Börje S. Andersson

19.9k total citations · 2 hit papers
326 papers, 13.4k citations indexed

About

Börje S. Andersson is a scholar working on Hematology, Oncology and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Börje S. Andersson has authored 326 papers receiving a total of 13.4k indexed citations (citations by other indexed papers that have themselves been cited), including 238 papers in Hematology, 98 papers in Oncology and 96 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Börje S. Andersson's work include Hematopoietic Stem Cell Transplantation (148 papers), Acute Myeloid Leukemia Research (117 papers) and Acute Lymphoblastic Leukemia research (95 papers). Börje S. Andersson is often cited by papers focused on Hematopoietic Stem Cell Transplantation (148 papers), Acute Myeloid Leukemia Research (117 papers) and Acute Lymphoblastic Leukemia research (95 papers). Börje S. Andersson collaborates with scholars based in United States, Canada and Thailand. Börje S. Andersson's co-authors include Richard E. Champlin, Sergio Giralt, Issa F. Khouri, Donna Przepiorka, James Gajewski, Paolo Anderlini, Marcos de Lima, Koen van Besien, David F. Claxton and Daniel R. Couriel and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Börje S. Andersson

316 papers receiving 13.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Engraftment of Allogeneic Hematopoietic Progenitor Cells With Purine Analog-Containing Chemotherapy: Harnessing Graft-Versus-Leukemia Without Myeloablative Therapy

1997 909 citations Sergio Giralt, Koen van Besien et al. Blood profile →
Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies.

1998 738 citations Issa F. Khouri, M Körbling et al. profile →

Peers

Countries citing papers authored by Börje S. Andersson

Since Specialization

Citations

This map shows the geographic impact of Börje S. Andersson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Börje S. Andersson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Börje S. Andersson more than expected).

Fields of papers citing papers by Börje S. Andersson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Börje S. Andersson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Börje S. Andersson. The network helps show where Börje S. Andersson may publish in the future.

Co-authorship network of co-authors of Börje S. Andersson

This figure shows the co-authorship network connecting the top 25 collaborators of Börje S. Andersson. A scholar is included among the top collaborators of Börje S. Andersson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Börje S. Andersson. Börje S. Andersson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Enhancement of High-Dose Chemotherapy and Autologous SCT with the PARP Inhibitor Olaparib for Refractory Lymphoma 2025 ·Clinical Cancer Research ·Yago Nieto, Jeremy Ramdial, Benigno C. Valdez, Peter F. Thall, Roland L. Bassett, M. J. Barnett, Samer A. Srour, Chitra Hosing, Amin M. Alousi, Muzaffar H. Qazilbash, Uday Popat, Alison Gulbis, Terri Lynn Shigle, Sairah Ahmed, (unknown), Richard E. Champlin, Elizabeth J. Shpall, Börje S. Andersson	1
2	Synergistic Cytotoxicity of Histone Deacetylase and Poly-ADP Ribose Polymerase Inhibitors and Decitabine in Breast and Ovarian Cancer Cells: Implications for Novel Therapeutic Combinations 2024 ·International Journal of Molecular Sciences ·Benigno C. Valdez, Apostolia M. Tsimberidou, Bin Yuan, Mehmet A. Baysal, Abhijit Chakraborty, Clark R. Andersen, Börje S. Andersson	2
3	Reprogramming T cell differentiation and exhaustion in CAR-T cell therapy 2023 ·Journal of Hematology & Oncology ·Yannick Bulliard, Börje S. Andersson, Mehmet A. Baysal, Jason S. Damiano, Apostolia M. Tsimberidou	45
4	Autologous engineered T cell receptor therapy in advanced cancer 2023 ·Human Vaccines & Immunotherapeutics ·Apostolia M. Tsimberidou, Mehmet A. Baysal, Abhijit Chakraborty, Börje S. Andersson	4
5	T-cell receptor-based therapy: an innovative therapeutic approach for solid tumors 2021 ·Journal of Hematology & Oncology ·Apostolia M. Tsimberidou, (unknown), Henry Hiep Vo, Stephen Eck, Yu‐Feng Lin, Jorge Mauricio Rivas, Börje S. Andersson	105
6	Fractionated busulfan myeloablative conditioning improves survival in older patients with acute myeloid leukemia and myelodysplastic syndrome 2021 ·Cancer ·Betül Oran, Rima M. Saliba, Rohtesh S. Mehta, Amin M. Alousi, David Marín, (unknown), Julianne Chen, Qaiser Bashir, Stefan O. Ciurea, Amanda Olson, Chitra Hosing, Partow Kebriaei, Katy Rezvani, Elizabeth J. Shpall, Richard E. Champlin, Börje S. Andersson, Uday Popat	3
7	Hematopoietic Stem Cell Transplantation for Severe Thalassemia Patients from Haploidentical Donors Using a Novel Conditioning Regimen 2020 ·Biology of Blood and Marrow Transplantation ·Usanarat Anurathapan, Suradej Hongeng, Samart Pakakasama, Duantida Songdej, Nongnuch Sirachainan, (unknown), Ampaiwan Chuansumrit, Pimlak Charoenkwan, Arunee Jetsrisuparb, Kleebsabai Sanpakit, Piya Rujkijyanont, (unknown), (unknown), (unknown), Pacharapan Surapolchai, (unknown), Rosarin Sruamsiri, Pustika Amalia Wahidiyat, Börje S. Andersson	46
8	Comparison of Outcomes of Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma Using Three Different Conditioning Regimens 2019 ·Biology of Blood and Marrow Transplantation ·(unknown), Paul Lin, Rima M. Saliba, Uday Popat, Qaiser Bashir, Nina Shah, Krina K. Patel, Simrit Parmar, Partow Kebriaei, Chitra Hosing, Stefan O. Ciurea, Börje S. Andersson, Elizabeth J. Shpall, Richard E. Champlin, Samer A. Srour, Muzaffar H. Qazilbash	10
9	Allogeneic Cord Blood Regulatory T Cells Can Prevent Graft Vs. Host Disease and Preserve Graft Vs Leukemia Effect: Update on Phase I/II Clinical Trial 2019 ·Blood ·(unknown), Hongbing Ma, Uday Popat, Yago Nieto, Stefan O. Ciurea, Amanda Olson, (unknown), Meixian Huang, Mitsutaka Nishimoto, Muzaffar H. Qazilbash, (unknown), Elizabeth J. Shpall, Richard E. Champlin, Simrit Parmar, Börje S. Andersson	1
10	Early Post-Transplant Minimal Residual Disease Assessment Improves Risk Stratification in Acute Myeloid Leukemia 2018 ·Biology of Blood and Marrow Transplantation ·Mithun Vinod Shah, Jeffrey L. Jorgensen, Rima M. Saliba, Sa A. Wang, Amin M. Alousi, Börje S. Andersson, Qaiser Bashir, Stefan O. Ciurea, Partow Kebriaei, David Marín, Keyur P. Patel, Uday Popat, Katy Rezvani, Gabriela Rondón, Elizabeth J. Shpall, Richard E. Champlin, Betül Oran	52
11	Development of an assay for cellular efflux of pharmaceutically active agents and its relevance to understanding drug interactions 2017 ·Experimental Hematology ·Benigno C. Valdez, Moustapha Hassan, Börje S. Andersson	5
12	Cladribine, gemcitabine, busulfan, and SAHA combination as a potential pretransplant conditioning regimen for lymphomas: A preclinical study 2016 ·Experimental Hematology ·Jie Ji, Benigno C. Valdez, Yang Li, Fulai Liu, Esmeralda C. Teo, Yago Nieto, Richard E. Champlin, Börje S. Andersson	5
13	Allogeneic Transplantation in First Remission Improves Outcomes Irrespective of FLT3-ITD Allelic Ratio in FLT3-ITD–Positive Acute Myelogenous Leukemia 2016 ·Biology of Blood and Marrow Transplantation ·Betül Oran, Jörge E. Cortes, Amer Beitinjaneh, Hsiang-Chun Chen, Marcos de Lima, Keyur P. Patel, Farhad Ravandi, Xuemei Wang, Mark Brandt, Börje S. Andersson, Stefan O. Ciurea, Fábio Pires de Souza Santos, Leandro de Pádua Silva, Elizabeth J. Shpall, Richard E. Champlin, Hagop M. Kantarjian, Gautam Borthakur	59
14	High Busulfan Exposure Is Associated with Worse Outcomes in a Daily i.v. Busulfan and Fludarabine Allogeneic Transplant Regimen 2008 ·Biology of Blood and Marrow Transplantation ·Michelle Geddes, (unknown), (unknown), Diana Quinlan, M. Ahsan Chaudhry, Douglas A. Stewart, Mary Lynn Savoie, Nizar J. Bahlis, Christopher Brown, Jan Storek, Börje S. Andersson, James A. Russell	101
15	Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: Study of pharmacokinetics and early clinical outcomes 2002 ·Biology of Blood and Marrow Transplantation ·Jeffrey A. Russell, Hai T. Tran, Diana Quinlan, A Chaudhry, Peter Duggan, Chris Brown, Douglas A. Stewart, Joseph D. Ruether, Donald G. Morris, Stefan Glück, (unknown), Börje S. Andersson	220
16	Recurrence of hodgkin's disease after indium-111 and yttrium-90 labeled antiferritin administration 1997 ·Cancer ·Huibert M. Vriesendorp, Syed M. Quadri, Börje S. Andersson, (unknown), (unknown)	5
17	Invasive Aspergillus sinusitis During Bone Marrow Transplantation 1997 ·Scandinavian Journal of Infectious Diseases ·Claire F. Verschraegen, Koen van Besien, (unknown), Jeane P. Hester, Börje S. Andersson, Elias Anaissie	20
18	Fludarabine (famp)-based chemotherapy at conventional doses allows engraftment of allogeneic (allo) peripheral blood progenitor cell (pbpc) transplantation in chronic lymphocytic leukemia (cll) 1996 ·Experimental Hematology ·Issa F. Khouri, (unknown), Börje S. Andersson, Susan O’Brien, M Körbling, (unknown)	1
19	Allogeneic bone marrow transplantation for poor-prognosis lymphoma: Response, toxicity, and survival depend on disease histology 1996 ·The American Journal of Medicine ·Koen van Besien, Rakesh Mehra, Sergio Giralt, Hagop M. Kantarjian, William Pugh, Issa F. Khouri, Young Soo Moon, P. Williams, Börje S. Andersson, Donna Przepiorka, Philip L. McCarthy, James Gajewski, (unknown), Fernando Cabanillas, R. Champlin	87
20	Prophylaxis of cytomegalovirus infection with ganciclovir in allogeneic marrow transplantation 1991 ·European Journal Of Haematology ·Jonathan C. Yau, Meletios Α. Dimopoulos, S. Huan, Jeffrey J. Tarrand, V. Spencer, Gary Spitzer, C Meneghetti, Ralph O. Wallerstein, Börje S. Andersson, C. Frederick LeMaistre	20

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact